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Abstract: 
 
The development of effective therapies for stroke continues to face repeated translational 
failures. Brain endothelial cells form paracellular and transcellular barriers to many blood-borne 
therapies and the development of efficient delivery strategies is highly warranted. Here, in a mouse 
model of stroke, we show selective recruitment of clinically used liposomes into the ischaemic 
brain that correlates with biphasic blood brain barrier (BBB) breakdown. Intravenous 
administration of liposomes into mice exposed to transient middle cerebral artery occlusion took 
place at early (0.5h and 4h) and delayed (24h and 48h) timepoints, covering different phases of 
BBB disruption after stroke. Using a combination of in vivo real-time imaging and histological 
analysis we show that selective liposomal brain accumulation coincides with biphasic 
enhancement in transcellular transport followed by a delayed impairment to the paracellular 
barrier. This process precedes neurological damage in the acute phase and maintains long-term 
liposomal co-localisation within the neurovascular unit, which could have great potential for 
neuroprotection. Levels of liposomal uptake by glial cells are similarly selectively enhanced in the 
ischaemic region late after experimental stroke (2-3 days), highlighting their potential for blocking 
delayed inflammatory responses or shifting the polarization of microglia/macrophages towards 
brain repair.  
 
These findings demonstrate the capability of liposomes to maximise selective translocation into 
the brain after stroke and identify two windows for therapeutic manipulation. This emphasizes the 
benefits of selective drug delivery for efficient tailoring of stroke treatments. 
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Stroke is a devastating neurological condition and a leading cause of death and disability 
worldwide, yet treatment options are extremely limited and thus represent an area of unmet 
clinical need 1, 2. At present, restoration of blood flow with thrombolysis and/or thrombectomy 
are the only licensed treatments for ischaemic stroke, however these options can only be 
administered up to 4.5h post-stroke, benefitting only a minority of patients3. While reperfusion 
strategies are effective in opening up occluded cerebral vessels in some patients, there are 
currently no approved treatments for the myriad of damaging pathological processes that persist 
in the brain long after the acute stage such as oxidative stress and inflammation4 .Therefore, 
targeting these downstream pathophysiological processes could hold great therapeutic potential. 
However considerable research effort has been invested over the last 30 years into the 
development of novel neuroprotective treatments, with a lack of success5. There are many 
possible explanations for this translational failure, but  insufficient concentrations of drug that 
reach the intended target area is likely a major factor 6. Another important problem is the time 
window between the onset of stroke and treatment initiation which has been frequently wider in 
clinical trials compared to successful experimental stroke studies 4. Therefore, developing 
technologies that can circumvent inefficient brain delivery and/or unfavourable distribution and 
safety profiles would lend different prospect to already existing therapeutics. 
 
In normal conditions, brain endothelial cells (BECs), through tightly regulated transcellular 
transport and tight junction (TJ) proteins7, are the primary regulators for the entry of blood-borne 
molecules into the brain. During stroke there is strong evidence from preclinical8-10 and clinical11, 
12 studies that blood brain barrier (BBB) integrity is compromised. Ischaemic conditions 
affecting the brain tissue alter the rate and the extent of BEC transcellular transport and change 
the expression levels and localisation of TJ proteins9. Moreover, degradation of extracellular 
matrix by proteolytic enzymes (such as matrix metalloproteinases) 13, 14, release of inflammatory 
mediators and infiltration of peripheral blood leukocytes 15 have all been proposed to contribute 
to BBB hyperpermeability after ischaemic stroke. As a result, a biphasic increase in BBB 
hyperpermeability and uncontrolled entry of molecules to the brain occurs. The exact 
contribution of transcellular and paracellular pathways to BBB hyperpermeability after 
ischaemic stroke is a matter of controversy16. However, the most accepted model of 
hyperpermeability is characterised by; a) an early phase (occurring a few hours post stroke) of 
enhanced transcellular transport mediated by increases in endothelial vesicles termed caveolae, 
followed by b) a delayed phase of hyperpermeability (~ 2d post-stroke) in which both enhanced 
transcellular transport and TJ proteins disassembly contribute to the loss of BBB integrity9. This 
two-phase model is supported by recent evidence in which endothelial TJs were labelled with 
eGFP, allowing the dynamics of TJ integrity after stroke in mice to be monitored in vivo in real 
time9. Similarly, in a rat model of stroke it was shown that BBB opening to macromolecules 
(transcellular route) precedes permeability to small ions (paracellular route)17. Moreover, recent 
findings in a comorbid rodent model of ischaemic stroke, reported a significant exacerbation to 
the BBB disruption when combined with other diseases without necessarily altering the 
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underlying sequence of events behind BBB disruption10. Consequently, BECs that survive the 
ischaemic damage, but do not maintain BBB integrity, can in fact worsen the damage to the brain 
parenchyma and thus accelerate disease progression 18. On the other hand the disrupted BBB 
could act as a gate for therapeutic access7. This highlights the need for more effective delivery 
approaches that can selectively and efficiently penetrate areas of BBB hyperpermeability 
compared to other brain regions where BBB permeability is unaffected. 
 
In the past few decades, nanotechnology-based drug delivery approaches such as liposomes 
have demonstrated a great potential to improve the pharmacokinetics and biodistribution profile 
of many small drug molecules. Selective accumulation of liposomes into the disease site, such as 
a tumour, is mediated by hyperpermeability of endothelial cells and impaired lymphatic drainage 
compared to other healthy organs. This phenomenon is collectively known as the enhanced 
permeability and retention (EPR) effect19, which is behind the clinical use of many liposomal-
based medications20. Previous studies have shown that endothelial cell hyperpermeability is 
mediated by one or more of the following pathways; a) fenestrations in the basement 
membrane21, b) paracellular transport through gaps between endothelial cells21, and c) 
transcellular route mediated by vascular transport (caveolae)22. These pathways are in great 
analogy to BECs structural adaptations after ischaemic stroke and, therefore, highlight the 
possibility that liposomes might be equally effective in the treatment of stroke by providing 
selective and enhanced drug delivery to the ischaemic brain. In this respect there are a few 
promising examples of liposomal treatment of ischaemic stroke reported recently23-28. However, 
the focus of those studies is restricted to the acute phase (<1-3h) after ischaemic reperfusion and 
they did not fully address longer-term pathological consequences and the practicality of clinical 
translation. Given that the main aim of neuroprotective treatment of stroke is to expand the 
therapeutic window compared to thrombolytic therapies, an in depth understanding of the 
window of BBB opening after stroke is required to fully achieve the potential of liposomes as a 
drug delivery approach. 
 
The aim of this study was to fully interrogate the validity of utilizing liposomes to maximise 
drug delivery in stroke. Multiple quantitative (e.g. DiI-Lp intensity, % of ID of 111In-DTPA-Lp) 
and qualitative techniques (e.g. SPECT/CT, IVIS, confocal imaging and in vivo multiphoton 
imaging) were employed to establish the time window and mechanism of liposomal 
accumulation into the brain after experimental stroke in mice. Early and delayed accumulation of 
liposomes into the brain were evaluated and time points that gave rise to key brain accumulation 
are highlighted for future therapeutic evaluation.  
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Results  
In order to establish the validity of liposomes for selective drug delivery into the ischaemic 
brain, we have applied in vivo and ex-vivo imaging techniques to study their recruitment into the 
brain after stroke. A liposomal formulation based on the composition of clinically used liposome 
(Doxil®, HSPC:CHOL:DSPE-PEG2000) was selected, as this has proved to have excellent blood 
circulation time and very good drug retention capability once inside the body29 (For 
characterisation data please see Figure S1). Selective recruitment of liposomes into the brain 
was studied in a preclinical model of middle cerebral artery occlusion (MCAo) followed by 
reperfusion.  
 
Selective liposomal accumulation into the ischaemic brain correlated with biphasic BBB 
breakdown induced by stroke. Liposomal accumulation into the ischaemic brain was first 
studied shortly after intravenous (I.V) administration of fluorescently-labelled liposomes (DiI-
Lp). Each group of mice received a single I.V injection of DiI-Lp. The time points of injections 
were carefully selected to cover the two-phases of BBB damage after ischaemic stroke as 
previously reported 9. IVIS Lumina II imaging (Figure 1A) confirmed the selective accumulation 
of liposomes into the ischaemic left side of the brain as early as 2h after DiI-Lp I.V 
administration compared to minimum detection from the contralateral side of the brain (right) 
and healthy mice (naïve mice injected with DiI-Lp). Quantification of the total fluorescent signal 
of liposomes in the brain indicated that the accumulation of liposomes significantly increased 
when injected at 0.5h or 48h after MCAo and reperfusion, by 4.6-fold at both time points, 
compared to healthy mice injected with DiI-Lp (Figure 1B). In contrast 2-fold increase in DiI-Lp 
accumulation observed when injected 4h and 24h after MCAo and reperfusion. This suggested 
that liposomal brain accumulation induced by stroke is correlated with the biphasic BBB 
breakdown in agreement with previous reports.9, 14, 30, 31 Histological analysis of the brain tissue 
confirmed that the selective liposomal accumulation into the ischaemic area has the same 
distribution to BBB disruption (Figure 1D), as seen by infiltration of endogenous 
immunoglobulin (IgG). Selective brain accumulation covered both ipsilateral striatum and cortex 
when injected 0.5-2.5h and 48-50h after MCAo. 
 
Liposomal brain accumulation in the acute phase post ischaemic stroke preceded neurological 
damage. Cerebral accumulation of DiI-Lp injected at the early phase after MCAo and 
reperfusion (0.5-2.5h & 4-6h) were observed as early as 2h after I.V administration, before the 
observation of significant histological evidence of neuronal cell death (Figure 1C&D). Infarct 
volume measurements were ~ 5 mm3 for 0.5-2.5h and 4-6h groups compared to > 30 mm3 
observed for 24-26h and 48-50h groups. This early accumulation was associated with rare 
instances of vessel lumen collapse as seen by H&E staining (Figure 1D), but in the absence of 
any active bleeding process.  
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Liposomes maintained selective accumulation in the ischaemic area of the brain 24h after I.V 
administration. Selective enhancement of cerebral accumulation of DiI-liposomes given 0.5h 
and 48h after reperfusion was still observed in the ischaemic region 24h after their I.V injection. 
Quantification of DiI-Lp signal in the brain indicated 7.2-fold and 3.9-fold increase compared to 
healthy mice at 0.5-24.5h and 48-72h, respectively (Figure 2C). DiI-Lp cerebral accumulation 
covered both ipsilateral cortex and striatum and maintained similar distribution to the areas of 
BBB damage and infarct as seen with IgG infiltration and Cresyl violet stain respectively (Figure 
2D). Liposomal accumulation at the time windows of maximum selective recruitment into the 
brain (0.5h & 48h) were also studied in real time by SPECT-CT imaging (Figure 3A) using 111In-
DTPA-liposomes (111In-Lp). Characterisation data of 111In-Lp and radiolabelling efficiency are 
explained in Figure S2. During real time SPECT/CT imaging the selective recruitment of 
liposomes in the brain became more apparent 24h after injection since immediately after 
injection the high level of liposomes in the blood gave rise to equal signal from both sides of the 
brain (Figure 3B). Quantification of 111In-Lp accumulation 24h after I.V administration 
confirmed significant increase in ipsilateral accumulation of 111In-Lp when injected at 0.5h or 
48h after MCAo (Figure 3E). On the contrary no significant difference in 111In-Lp levels was 
detected in the contralateral region (Figure 3F). Measurements of 111In-Lp in the cerebrospinal 
fluid (CSF) (Figure 3G) indicated no significant increase in liposomal clearance into the CSF 
after MCAo, which explained the persistence of liposomes in the ischaemic area even 1d after 
administration. 
 
Biphasic increase in liposomal brain accumulation after ischaemic stroke connected with 
enhanced transcellular transport. 
To gain an in depth understanding of the mechanisms of selective liposomal recruitment into the 
brain after stroke, we investigated the molecular pathways (transcellular vs paracellular) that 
could be involved. Experimental MCAo model leads to a biphasic increase in transcellular 
transport across the BBB in the early and delayed phases after ischaemia (Figure 4A). However, 
it is unclear if enhanced transcellular transport (endothelial caveolae) is connected to the 
biphasic increase in liposomal brain accumulation after ischaemic stroke. Caveolae are 
invaginations of plasma membrane that play an important role in the transcellular transport of 
small molecules such as cholesterol and albumin 32. Among the caveolins family, caveolin-1 
(Cav-1) is known as an important regulator of caveolin mediated transport. The exact 
contribution of Cav-1 to BBB hyperpermeability is not clear, though recent findings indicate 
enhanced Cav-1 expression by BECs and increased numbers of transcellular vesicles shortly 
after ischaemic insult and before TJ disassembly 9, 33, 34. Moreover, Knowland et al confirmed 
that this effect is in fact biphasic and contributes to both early and late BBB disruption 9. 
Consistent with previous reports 35, 36, TEM images of brain tissues in the acute (MCAo+2.5h) 
and late (MCAo+50h) phases after stroke (Figure 4B) confirmed ultrastructural changes in 
endothelial cells compared to healthy brains. Increases in caveolae numbers were clearly 
evident in the cytoplasm of BECs at both time points. Enlargement of the vesicles and 
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ultrastructural changes to endothelial cell TJs (protrusions and change in morphology) were also 
observed at the late but not the early time point after MCAo. These observations were further 
confirmed by immunofluorescence labelling of endothelial CD31 and Cav-1 markers. We 
transcardially perfused the animal with PBS under terminal anaesthesia prior to fixing the brain 
with 4% PFA. This perfusion ensures removal of any circulating liposomes, meaning that only 
liposomes taken up by brain endothelial cells (co-localised with CD31) or those extravasated 
into the brain parenchyma would be imaged (Figure S3). Analysis of the brain tissues 2h after 
intravenous administration of DiI-Lp revealed a biphasic increase in Cav-1 expression from 
0.5h (MCAo+2.5h) and 48h groups (MCAo+50h) at 53% ± 14% and 28% ± 5.8, respectively. 
Areas of enhanced Cav-1 expression co-localised with the areas of DiI-Lp leakage into the 
ischaemic brain (Figure 4C&D). Similar observations were detected in the ipsilateral cortex, 
however to a slightly lesser extent (Figure S4). On the contrary, Cav-1 expression and 
accumulation of DiI-Lp in the brain were minimum from MCAo groups injected at 4h & 24h 
post stroke. Similarly, low level of basal Cav1 staining was observed in the healthy brain 
(Figure 4C and Figure 4SC) and in the contralateral sides (Figure S6 & Figure S7) which 
explains limited DiI-Lp accumulations in those cases. Our data agree with Knowland et al 
observations 9, where they showed limited basal Cav1 expression in the healthy and 
contralateral side and a significant increase in Cav1 expression in the ipsilateral side after 
MCAo.  
 
To confirm the role of caveolae in the uptake of liposomes by brain endothelial cells, we have 
used dynasore, a pharmacological inhibitor of caveolar transport in hCMEC/D3 brain 
endothelial cells in vitro. Consistent with our in vivo data, we observed a significant reduction 
(~ 80%) in DiI-Lp uptake by hCMEC/D3 cells in the presence of dynasore (Figure 3E). In 
comparison, no significant reduction in DiI-Lp cellular uptake was observed with 
chlorpromazine, an inhibitor of clathrin-mediated transport. Overall, our data suggested that 
caveolae is the main pathway behind liposomes mediated transcytosis through brain endothelial 
cells. 
 
Evaluation of DiI-Lp localisation 24h following I.V at 0.5h and 48h to MCAo mice (Figure 3F) 
indicated that substantial numbers of liposomes maintain their co-localisation in the 
neurovascular unit (NVU) in areas of enhanced Cav-1 expression (Figure 4E & Figure S5). 
 
Delayed liposomal brain accumulation after ischaemic stroke co-localised with regions of 
impaired paracellular barrier 
In addition to enhanced transcellular transport, compromised paracellular barrier by virtue of TJ 
proteins disassembly leads to BBB disruption after ischaemic stroke. Up to 30% of TJ strands 
were reported to be open 48–58h after MCAo and the opening of these gaps increased 
progressively after stroke, reaching gaps of 0.2-1.2 µm9. Since the size of TJ opening is far 
bigger than the hydrodynamic diameter of liposomes tested in this study (120-130nm) it is 
8 
 
feasible that the delayed phase of liposomal accumulation is facilitated by the paracellular route. 
To test this, mice were implanted with a cranial window underwent MCAo surgery and received 
DiI-Lp intravenously at 0.5h or 48h after MCAo. Together with DiI-Lp injections, mice also 
received I.V injections of fluorescent tracers for paracellular pathway (dextran 3k) and 
transcellular pathway (albumin-Alexa488). Previous studies have demonstrated that loss of TJ 
integrity results in increased vascular permeability to markers ranging from 0.5 to 300 kDa. 
Therefore, we have selected dextran 3kDa for this study as it is within that molecular weight 
range and at the same time being not a very large molecule can allow the detection of even slight 
changes in TJ integrity 37. This is important to prove that TJ integrity is maintained in the early 
phase after MCAo as selecting a dextran molecule with a larger molecular weight might give a 
negative indication of the absence of paracellular transport due to a size exclusion effect 38. To 
examine the dynamic accumulation of liposomes into the ischaemic brain and correlate that with 
structural abnormalities of BECs, we subjected MCAo mice to in vivo multiphoton imaging 
recording at 30 min and 2 h after DiI-Lp and tracers injections. These time points were selected 
to match our previous data sets and offered the advantage of having both time points in the same 
animal.  
 
Dextran is normally excluded from the brain parenchyma by an intact TJ as can be seen from 
multiphoton images (Figure 5B), however, its extravasation from the blood vessels increased by 
2-fold in the late phase after ischaemic stroke progression (Figure 5C). This extravasation 
became apparent at 48-50h after MCAo and reperfusion, correlating with the TJ disassembly. In 
contrast, albumin uptake by BECs was reported to be through caveolae mediated endocytosis39, 
thus its accumulation into the brain increased by 5.9-fold in the acute phase (0.5-2.5h) and by 3-
fold in late phase (48-50h) after MCAo (Figure 5B&C). These observations corroborated our 
previous findings from TEM and IHC analysis, suggesting that BBB permeability in the early 
phase is mediated mainly by enhanced transcytosis. This is also in agreement with other recent 
studies of BBB permeability in MCAo model 9, 10. The observations of real time multiphoton 
imaging were further validated ex vivo using IVIS of the brain which again demonstrated 
biphasic enhancement in albumin and DiI-Lp after stroke, compared to only delayed 
accumulation of dextran at 48-50h after MCAo (Figure 5D&E). 
 
Overall, our data suggest that biphasic upregulation of transcellular pathway followed by 
delayed TJ disassembly are the drive for the selective liposomal accumulation into the ischaemic 
side of the brain (Figure 5B&C). Although Cav-1 is known to be essential for transcellular 
transport of albumin through BECs, recent observations showed that albumin uptake could still 
be enhanced in Cav-1 deficient mice, though to a lesser extent, which imply the contribution of 
other Cav1-independent pathways9. Moreover, previous studies have also reported that the 
transcytosis rate of endothelial cells is also affected by other factors such as; changes in Cav-1 
phosphorylation 40, loss of Mfsd2a (major facilitator superfamily domain containing 2a) 
expression (suppressor of transcytosis) 41 or upregulation of other transcytosis proteins such as 
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Cavin-1, Cavin-2 32. Therefore, it would be important to investigate the correlation of those 
factors to enhanced liposomal accumulation in the brain in the future.  
 
Selective targeting of ischaemic brain with liposomes offers time-dependent tailoring of stroke 
treatment. Immunobiological analysis described above indicated that liposomes administered in 
the acute (0.5h) and late (48h) phases after stroke co-localised with the NVU. Since the NVU 
plays a critical role in the progression of ischaemic damage after stroke, selective targeting of the 
NVU with liposomes, particularly in the acute phase, could hold great potential as a therapeutic 
strategy by limiting the deleterious effects of BBB disruption after stroke. 
 
In addition to the NVU, co-localization of the liposomes with other cellular compartments of 
the brain parenchyma was tested. Immunostaining for ionised calcium binding adaptor molecule 
1 (Iba-1), which is exclusively expressed by macrophages and microglia and glial fibrillary 
acifdic protein (GFAP), expressed by astrocytes, was performed (Figure 6). The uptake of 
fluorescently labelled liposomes (DiI-Lp) by microglia and astrocytes was investigated with 
confocal microscopy by measuring the co-localisation of DiI-Lp signal with Iba-1 and GFAP 
+ve areas. Confocal images showed very limited liposomal uptake by astrocytes at both time 
points (Figure 6A). Where as a clear uptake was observed by microglia only at the 48-50h after 
MCAo (Figure 6B&C) which was not observed 0.5-2.5h after MCAo (Figure 6A). These 
observations were confirmed by quantification of the percentage of DiI-Lp uptake by Iba1+ cells 
and GFAP+ cells which was performed 24h after I.V administration of DiI-Lp. We found that a 
significant fraction (40-50%) of DiI-Lp co-localised with Iba1+ cells when administered 2 days 
after MCAo compared to <3-4% when injected in the acute phase, at 0.5h after MCAo (Figure 
6F). Resting microglia dynamically monitor the brain microenvironment 42, and become 
activated when sensing damaging signals, changing morphology from long, ramified protrusions 
to shorter, hyper-ramified branches 43. Our results demonstrate DiI-Lp uptake by both resting and 
activated microglia, though it is enhanced in the latter (Figure 6G). In contrast, less uptake (< 
5%) of DiI-Lp by Iba-1 +ve cells was observed in the ipsilateral cortex at both time point (Figure 
S8). Minimum uptake of DiI-Lp by astrocytes was observed at both times tested both in the 
ipsilateral striatum (Figure 6H) and cortex (Figure S8). No specific uptake of DiI-Lp by neurons 
was detected at the time points tested, while occasional co-localisation with MBP+ cells 
(oligodendrocytes) was observed (Figure S9 & Figure S10).  
 
Discussion  
 
Stroke-induced BBB disruption results in a biphasic enhanced entry of blood borne molecules 
to the brain. Despite the obvious benefits this can offer to enhance drug delivery to the ischaemic 
brain, this area has been largely overlooked. Understanding the link between the response of 
BECs in vivo to ischaemic injury and selective drug delivery to the brain is crucial to the 
development of timely therapies that may halt disease progression.  
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Recent studies using nanoparticles-based delivery systems demonstrated the possibility to 
selectively target the lesion area after experimental stroke. This effect was only demonstrated 
when those nanoparticles injected I.V just before reperfusion or 1-3 h afterward 44, 45. Although 
these studies suggested that the increase in the permeability of the BECs is the drive for this 
selective accumulation, no direct correlation to BBB damage was reported. Moreover, the exact 
mechanisms by which the selective brain localization happens are largely unknown and require 
in depth studies. Therefore, in this study we systematically interrogated the benefit of BBB 
damage to enhance drug delivery by analysing the brain accumulation and localisation of I.V 
liposomes injected at different time points after experimental stroke to cover the biphasic 
increase in BBB permeability. The most acceptable model of BBB response to ischemia involves 
a stepwise activation of two distinctive pathways, starting with enhanced BECs transcellular 
transport early after reperfusion followed by a second delayed phase (~48h post stroke) of 
enhanced transcellular transport and major disassembly to TJ protein complexes 9, 46.Here we 
demonstrate that biphasic BBB hyperpermeability after stroke correlates with selective 
enhancement of liposomes accumulation into the ischaemic brain. More specifically we 
identified two distinct windows for maximum localisation of liposomes into the brain; an early 
phase (0.5h after stroke) that agrees with previous studies, and a delayed phase (48h after stroke) 
which has not been reported before. These observations were based on in vivo (SPECT/CT and 
multiphoton imaging) and ex-vivo (IVIS) imaging techniques and were further confirmed by 
histological analysis. We have demonstrated that enhanced transcellular transport is the main 
mediator for increase liposomal brain accumulation in the early phase (0.5h). Whereas the 
reduction in the level of these vesicles in the time between 4h and 24h after stroke is behind the 
minimal accumulation of liposomes observed at those time points. This agrees with previous 
studies that reported limited liposomal translocation or therapeutic effect from delivery systems 
administered around those times 44, 45. Our data also reveals a second window for liposomal entry 
into the brain (~48h after stroke) in which both transcellular and paracellular pathways contribute 
to the selective localisation of liposomes.  
 
The reasons behind the initial increase in transcellular transport through BECs after ischemia 
are not well defined yet. One possible explanation, correlates with the early migration of 
pericytes away from the BECs that is triggered after basement membrane dissolution 47, 48. 
Pericytes are known to secrete inhibitory signals that reduce the rate of transcellular transport 
through BECs. Thus, the loss of those inhibitory signals can lead to the initial rise in transcellular 
transport 49, 50. Caveolae are the intermediaries of this transcellular pathway and contain 
receptors to molecules that must cross the BBB 51, However, it is unclear if this increase has any 
benefit the to NVU at this stage after stroke9. The late increase in BBB hyperpermeability is 
more linked to TJ disassembly triggered by matrix metalloproteinases (MMPs), secreted by 
inflammatory cells, and angiogenic growth factors such as vascular endothelial growth factor and 
& nitric oxide synthase 9, 15. This comes in parallel with a second phase of increase in BECs 
transcytosis9. Although previous studies reported reduced level of TJ proteins (Claudin5, 
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Occludin, and Zona Occludens-1) in the first few hours after stroke 31, ultrastructural analysis of 
TJ during the evolution of ischaemic stroke are not persuasive that this reduction is responsible 
for the early BBB breakdown 34, 52. Based on the studies mentioned above, it is suggested that 
active disassembly of TJ proteins occur in the late phase of reperfusion, when angiogenesis of 
CNS vessels begins 53. This is also in agreement with our data that demonstrated TJ modification 
only 48h after MCAo. This was confirmed with TEM imaging of brain sections and multiphoton 
and IVIS imaging of dextran 3k extravasation into the brain.  
 
Identification of the exact therapeutic benefit of this selective brain delivery approach needs 
substantially more experimental work. Here we provide a clear evidence that selective 
accumulation of liposomes into the ischemic hemisphere precedes neuronal damage which make 
them ideal for neuroprotection. Few neuroprotective drugs have been tested in liposomal 
formulation injected at reperfusion or shortly after such as erythropoietin 26, tacrolimus 44 and 
CDP-choline 28. When compared to free drugs, promising therapeutic effects were reported 
including reduced cellular apoptosis, brain infarct volume and improved motor function. 
 
Beside protecting the brain tissue, NVU itself can be a therapeutic target. It is well known that 
disruption of the BBB markedly influences the pathogenesis of stroke. Moreover, both systemic 
and cerebrovascular inflammation contribute to further BBB disruption and can alter stroke 
prognosis. This effect is both neutrophil and MMPs dependent 54. Neutrophils are generally 
considered the first responders to ischaemic stroke as they infiltrate the brain within the first few 
hours after the ischaemic insult. Neutrophils have a key role in BBB disruption as they are the 
source of various proteolytic enzymes in particular MMPs. Consistent with that, recent studies 
indicated that active MMP2/9 observed in the brain after the initial disruption of BBB 
permeability, approximately 3h after ischemia 55, and progressively increased afterwards 56. In 
vitro and in vivo studies suggested that inhibition of MMP2/9 minimised BECs permeability and 
transiently reduced the infarct volume. Our immunobiological analysis indicated substantial co-
localisation of liposomes with NVU both in the early and delayed phases after stroke which was 
maintained even 24h after administration. The therapeutic potential of this has not been tested 
before. However due to the great influence of NVU on the progression of ischaemic damage 
after stroke, selective targeting of the NVU with liposomes, could be used to influence neutrophil 
infiltration and/or for MMPs inhibition in order to mitigate the deleterious effects of BBB 
disruption after stroke. 
 
Cerebral inflammation is also a key factor in neuronal damage after acute ischaemic injury 57. 
This is mainly mediated by the secretion of pro-inflammatory mediators by classically activated 
M1 microglia and macrophages such as interleukin-1 family which are triggered in response to 
sterile inflammation 58. However, recent studies highlighted the dual role of 
microglia/macrophages in brain disorders. In fact, alternatively activated M2 phenotype are the 
source of protective and neurotrophic factors that reserve brain function and promote brain 
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functional recovery 59. Therefore, blocking the inflammatory responses after stroke 60-62 or 
shifting microglia/macrophage polarisation towards brain repair 63 is another area of therapeutic 
potential. The present study is the first to identify the intriguing selective uptake of liposomes by 
microglia in the late phase after stroke and its correlation with microglia activation stage. 
Therefore, it will be essential to investigate the potential of liposomes to tip the central 
inflammatory responses after stroke towards brain repair. This would allow cell type specific 
intervention to be tested in timely manner after stroke.  
 
The therapeutic targets described above are driven by the natural tendency of selective 
liposomal accumulation into the brain post stroke, however, active targeting of specific cell 
population in the brain is another area worth of investigation. This concept can be highly relevant 
for delivering neuroprotective drugs to neurons early on after stroke, as liposomal accumulation 
in the brain was evident prior to neuronal cell loss. The approach we are describing could also be 
translated to other types of nanocarrier (e.g. polymeric nanoparticles, micelles, etc) that could 
utilise both delivery windows to translocate into the brain after stroke. However, a key advantage 
liposomes offer compared to other drug delivery approaches, is their ability to encapsulate 
hydrophilic and hydrophobic molecules. This makes them very attractive for stroke therapy, 
since the choice of encapsulated therapeutic molecules can be easily tailored to match the 
therapeutic target in a timely manner.  
 
Since treatment with therapeutic agents in the early phase after ischemia/reperfusion is 
necessary to preserve brain function, in future studies it is important to investigate the effect of 
this early intervention on BBB permeability at later time points (e.g. 48h) after stroke since this 
could be changed by the intervention. This is especially important if a dual targeted approach is 
utilised to deliver therapeutic molecules at both early and delayed phases after stroke. Another 
important factor to consider is the effect of stroke severity (MCAo occlusion time) on the timing 
and mechanism of liposomal brain accumulation into the brain after stroke. 
 
Limitations of the results 
In this study we have established the potential of utilizing liposomes to achieve selective 
enhanced translation in ischaemic brain after experimental stroke. We have identified two-
windows for maximum accumulation into the brain with two distinct therapeutic targets. What 
we haven’t showed in this study is the translation of this enhanced accumulation into improved 
therapeutic activity or functional recovery by encapsulating therapeutic molecules inside the 
liposomes. However, this study lays the basis for critical design of future therapeutic studies to 
prove the potential liposomes offer to accelerate the clinical translation of stroke treatments. 
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Conclusions 
 
We propose liposomal drug delivery to enhance the translocation of therapeutic molecules 
into the brain by taking advantage of BBB disruption induced by ischaemic stroke. Liposomal 
transport through the BBB deficits in experimental stroke is mediated by a stepwise impairment 
of transcellular followed by paracellular barriers. Our data revealed two windows for selective 
stroke treatment including; a) targeting the NVU in the acute phase to preserve the brain function 
and minimise the deleterious consequences of stroke, and b) targeting inflammatory cells in the 
ischaemic brain to shift their polarization towards brain repair. Future studies to test the 
therapeutic potential of liposomes in ischaemic stroke are warranted to prove their potential 
utility in accelerating the clinical translation of stroke treatments. 
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Materials and Methods 
Materials.  
Hydrogenated soy phosphatidylcholine (HSPC) and 2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were kind gifts 
from Lipoid GmbH (Ludwigshafen, Germany).18:0 PE-DTPA 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-diethylenetriaminepentaacetic acid (ammonium salt) was purchased 
from Avanti Polar Lipids (USA). Chloroform and methanol were purchased from Fisher 
Scientific. Phosphate buffer saline, cholesterol, paraformaldehydes were purchased from Sigma. 
1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (DiI) was purchased from 
Invitrogen Detection Technologies. Polycarbonate extrusion filters (Whatman) 800nm, 200nm, 
and 100nm were form VWR, UK. PD-10 desalting columns were bought from GE-Healthcare 
Life Sciences. 
 
Mice and diets 
C57BL/6 male mice (11-12-week-old, weighing 25-30 g; Envigo, UK) were housed in groups 
of 4–5. All mice were given free access to diet and water and were housed at a constant ambient 
temperature of 21 ± 2°C and humidity of 40–50%, on a 12-h light, 12-h dark cycle. All 
experimental procedures using animals were carried out according to the United Kingdom 
Animals (Scientific Procedures) Act, 1986 and approved by the Home Office and the local 
Animal Ethical Review Group, University of Manchester and reported in compliance with the 
ARRIVE guidelines.  
 
Studies design and exclusion criteria 
Calculations of sample sizes were based on power analysis of data from pilot studies and 
previous experiments. For DiI-Lp accumulation in the brain, we have estimated a mean value of 
4.0 E-5 for healthy mice and a mean value of 4.3 E-4 for MCAo mice with a SD of 1.05 E-4. 
Assuming a significance level of ≤ 0.05 and a power of 80%, the estimated sample size is n=3-4 
for detection of 60-70% difference. For the detection of 111In-Lp ID in the brain, the mean value 
for healthy mice is 0.04% of ID and MCAo mice is 0.24% with STD of 0.05% which gives a 
sample size of n=3-4 mice to detect a deference of 50-60%. 
 
The data were excluded from the analysis in the following conditions; 1) lack of sustained 
reduction in cerebral blood flow and 2) if signs of subarachnoid haemorrhage or seizure were 
observed. All experimental procedures using animals were carried out according to the United 
Kingdom Animals (Scientific Procedures) Act, 1986 and approved by the Home Office and the 
local Animal Ethical Review Group, University of Manchester and reported in compliance with 
the ARRIVE guidelines.  
 
Induction of focal cerebral ischaemia 
Focal ischaemic stroke was induced by transient middle cerebral artery occlusion (MCAο) as 
previously described10, 64. Briefly, under 2% isoflurane anaesthesia (in a mixture of 30 % oxygen 
and 70 % nitrous oxide), the carotid arteries were exposed and a 6–0 silicon rubber-coated 
monofilament (Doccol, USA) with a 2-mm tip (210μm diameter, coating length 405 mm) was 
inserted into the left common carotid artery and advanced along the left internal carotid artery 
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10mm after the left carotid bifurcation. Cerebral blood flow was monitored in all mice by laser-
Doppler (Moor Instruments, UK) and MCAo was confirmed by a drop in cerebral blood flow of 
at least 40-50% of baseline. If this drop in blood flow was not attained, animals were excluded 
from the analysis. After 20min occlusion, reperfusion was achieved by withdrawing the filament 
and the wound was sutured. During surgery, core body temperature was monitored using a rectal 
probe and maintained at 37 ± 0.5°C, using a homoeothermic blanket. Before recovery all mice 
were given saline (0.5 ml, S.C) and buprenorphine (0.05mg/kg S.C). After surgery, mice were 
weighed every day and assessed for their general well-being. Body weight data were presented 
as a % weight change compared with body weight on the day of surgery. Assessment of cerebral 
ischemia was performed using the a 28-point neurological scoring system65. Foot fault test was 
also performed to confirm ischaemic stroke model as previously described 64. At the end time 
point of each group, MCAo mice were placed on an elevated grid surface with grid openings of 
2.5cm2. During locomotion on the grid, the number of foot slips of both the ipsilateral and 
contralateral limbs was recorded. Ipsilateral refers the ischaemic side of the body (left) and 
contralateral limbs are those on the opposite side (right). Tests repeated for three times for each 
mouse and each trial lasted for 1min. An interval of at least 1min was kept between each trial. 
The total number of errors of each side is recorded and expressed as % of contralateral foot slips. 
 
Preparation of DiI-labelled liposomes (DiI-Lp) 
DiI-labelled liposomes composed of HSPC:Chol:DSPE-PEG2000 56.3:38.2:5.5 mol/mol % were 
prepared by thin film hydration method followed by extrusion. Briefly lipids dissolved in 
chloroform: methanol mixture (4:1) were mixed in round bottom flask and 5mol% of DiI in 
ethanol (1mg/ml) was added to the lipid mixture. Organic solvents were then evaporated to 
produce the lipid film66-68. Lipid films were kept protected from light and hydration was 
performed with HBS (20mM HEPES, 150mM NaCl, pH 7.4) to a final lipid concentration of 
12.5mM. To produce small unilamellar liposomes, the size was reduced by extrusion though 
800nm and 200nm polycarbonate filters 5 times each then 20-40 times through 100nm 
membranes using a mini-Extruder (Avanti Polar Lipids, Alabaster, AL). 
 
Preparation and characterisation of 111In-labelled liposomes (111In-Lp) 
To quantify and study the accumulation of liposomes into the brain in real-time SPECT/CT 
imaging and gamma counting of the liposomes were performed after radiolabelling with 
radioactive indium (111In). Briefly, 25mM (total lipid concentration) of HSPC:Chol:DSPE-
PEG2000:PE-DTPA 56.3:38.2:5.5:1 mol/mol % liposomes were prepared as described above 
using thin film hydration method. Hydration of the lipid film was done with freshly prepared 
ammonium acetate buffer (0.095M, pH 5.5) at 60°C followed by extrusion to reduce the size of 
the liposomes. Subsequently liposomes were radiolabelled by 1h incubation with radioactive 
111InCl3 (11MBq/2.5µmol lipids) in 2.0 M ammonium acetate pH 5.5. Incubation carried out at 
room temperature with continuous vortexing every 5 minutes. At the end of incubation 0.1M 
EDTA (1/20 of the total volume) was added to chelate any free 111In. To determine the 
Radiolabelling efficiency, any unbound 111In and 111In-EDTA were removed with PD-10 column 
pre-equilibrated with HBS pH 7.4. Aliquots of each final product were diluted five folds in PBS 
and then 1 μl was spotted on silica gel impregnated glass fibre sheets (PALL Life Sciences, UK). 
The strips were developed with a mobile phase of 50mM EDTA in 0.1M ammonium acetate and 
allowed to dry before analysis. This was then developed and the autoradioactivity quantitatively 
16 
 
counted using a Cyclone phosphor detector (Packard Biosciences, UK). The immobile spot on 
the TLC strips indicated the percentage of radiolabelled 111In-Lp, while free 111In was detected as 
the mobile spots near the solvent front. Very minimum free 111In was detected to yield 
radiolabelling efficiency of >85% as displayed in Figure S2. The radiolabelling stabilities of the 
final product of 111In-Lp were studied after five times dilution in both 50% serum or PBS and 
then incubated at 37°C up to 48h. At different time-points (0, 1 and 24h), 1μl of the aliquots was 
spotted on silica gel impregnated glass fibre sheets and then developed and quantified as 
described above. No significant release of 111InCl3 was detected after incubation with PBS and 
minimum free 111InCl3 was detected after incubation in 50% for 2 days (Figure S2). 
 
Liposomes characterization 
Liposome size and surface charge were measured using Zetasizer Nano ZS (Malvern, 
Instruments, UK). Samples were diluted 100 times with purified distilled water before 
measurements. Triplicates measurements were recorded, and the data expressed as average ± 
S.D. Fluorescen intensity of DiI-Lp was recorded using Carry Eclipse fluorescence 
spectrophotometer, (Agilent technology). Samples were first diluted 200 times in HBS and 
recorded at 518nm/565nm excitation/emission wavelengths (slit 5/10). 
 
Optical imaging of Lp-DiI accumulation into the brain  
Ex vivo optical imaging was used to study the accumulation of DiI-Lp into the brain by detecting 
the optical fluorescence signal of the liposomes. IVIS imaging was performed shortly after 
cardiac perfusion with iced-cold 0.9% saline followed by 4% PFA in order to remove any DiI-Lp 
that are still circulating in the blood. Brain tissues were extracted either 2h or 24h after I.V 
administration of DiI-Lp into MCAo mice (at 0.5h, 4h, 24h and 48h after 20min MCAo and 
reperfusion) and healthy mice. Imaging were performed with IVIS Lumina II imaging system 
(Caliper Life Sciences Corp., Alameda, CA) at 535nm/DsRed excitation and emission filters 
with 0.5 sec exposure. DiI-Lp total fluorescence intensity in the brain was quantified by drawing 
a region of interest (ROI) that covers the whole brain and expressed as total efficiency. We 
would like to emphasise that this method offers ‘semi-quantitative’ estimations of fluorescence 
intensity of the liposomes in the brain and the absolute quantification of the liposomes in the 
brain as % of I.D was measured in a separate experiment by gamma counting of 111In-liposomes 
(as explained below). 
 
Single photon emission computed tomography (SPECT/CT) 
Mice were subjected to anaesthesia via the inhalation of 2.5% isoflurane in a mixture of 30 % 
oxygen and 70 % nitrous oxide. Each animal was then intravenously injected with 200ul of the 
radioactive 111In-Lp (8-9 MBq). At different time points after injection (t= 0-1h, & 24h) 
SPECT/CT imaging was carried out using a Nano-Scan® SPECT/CT scanner (Mediso, 
Hungary). SPECT images were obtained in 20 projections over 40-60 min using a 4-head 
scanner with 1.4 mm pinhole collimators. CT scans were taken at the end of each SPECT 
acquisition using a semi-circular method with full scan, 480 projections, maximum FOV, 35 kV 
energy, 300 ms exposure time and 1-4 binning. Acquisitions were done using the Nucline v2.01 
(Build 020.0000) software (Mediso, Hungary), while reconstruction of all images and fusion of 
SPECT with CT images was performed using the Interview™ FUSION bulletin software 
(Mediso, Hungary). The images were further analysed using VivoQuant 3.0 software (Boston, 
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US) where the SPECT images with scale bars in MBq were corrected for decay and for the slight 
differences in radioactivity in the injected doses between animals. 
 
For a quantitative assessment of 111In-Lp in the brain, a cut and count method was used. Mice 
were anaesthetized by isofluorane inhalation and each mouse was injected via the tail vein with 
200μl containing 111In-Lp labelled with approximately 8-9 MBq. 24h after injection, mice were 
perfused with iced cold saline (0.9%) followed by PFA (4%) to remove any 111In-Lp from the 
blood before brain tissues were collected. Each sample was weighted and counted on a gamma 
Counter (Perkin Elmer, USA), together with a dilution of the injected dose with dead time limit 
below 60%. The results were represented as the percentage of the injected dose (% ID/gm tissue 
± SEM), n=4-5 mice per group.  
 
Cranial window implantation and multi-photon imaging 
Cranial windows were implanted following the protocol published by Goldey et. al 2014 69 
Animals were anesthetized with 2.5% isoflurane in 100% room air. After an injection of 
Metacam (50 µl SC in 1:10 water) and Dexafort (30 µl IM) the scalp was removed over the 
stroked hemisphere. Then a metal head plate was mounted (Narishige CP-2, Japan) to allow 
stereotaxic fixation under the two-photon microscope (Leica SP8 MP, UK HC FLUOTAR L 25x 
0.95 WATER dipping lens). A circular piece of bone with a diameter of 3mm and centred around 
the stereotaxic coordinates 2.8–3.35 mm left, 0.85–1.7 mm posterior relative to bregma. This 
region of interest exposes the somatosensory area of the cortex (specifically the barrel cortex) 
that is most affected by the MCAo. Once the skull was removed a circular cover slip (Warner 
Instruments, USA) was glued in its place using dental cement (Sun Dental, Japan). After the 
surgery animals were housed individually and allowed to recover for at least one week and 
monitored for normal behaviour like nest building and grooming. 
 
In vivo multiphoton imaging was carried out under 1.5% isoflurane anaesthesia in a 50:50 mix of 
oxygen and nitrous oxide at 0.5 hours and 48 hours after MCAo. Once anaesthesia was induced 
DiI-Lp (100µl), cascade blue dextran 3k (50µl) and Alexa-488 albumin (50µl) were injected via 
the tail vein. For the imaging itself we selected a stroked area of the brain that displayed different 
size vessels as well as large areas of parenchyma. 3D stacks were recorded up to a depth of 
150µm and z projection images calculated from these with ImageJ.  
 
In vitro cellular uptake studies of DiI-Lp by hCMEC/D3 cells 
 
In vitro cellular uptake study was performed with hCMEC/D3 cells, an extensively 
characterised model of brain endothelial phenotype and function, in order to get better insight on 
the mechanism of liposomal uptake. First, hCMEC/D3 cells were seeded in a 24 well plate at 
10,000 cells / well and allowed to adhere for 48 h before performing the cellular uptake study. To 
determine the role of caveolae mediated transcytosis in the uptake of liposomes, we incubated 
hCMEC.D3 cells with 0.5 mM of DiI-Lp for 17 h in the presence and absence of dynasore (25 µg/ 
ml) that inhibits dynamin dependent internalisation of caveolae 70, 71. As a control, we also tested 
DiI-Lp cellular uptake after inhibition of clathrin-mediated endocytosis using chlorpromazine 
(10µg / ml) 72. At the end of the incubation time, cells were washed twice with Optimum media 
and imaged using IncuCyte at Ex 518 nm and Em 565 nm to quantify cellular uptake. 
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Tissue processing 
Tissue processing was carried out 2h or 24h after liposomes injections. Mice were terminally 
anaesthetised with isoflurane and perfused transcardially with iced-cold 0.9% saline and then 
fixed with 4 % paraformaldehyde (PFA) in 0.1M phosphate buffer saline (PBS). Subsequently, 
brain samples were removed and post-fixed (in 4% PFA) overnight, cryoprotected in 30% 
sucrose for 1-2d and snap frozen in isopentane on dry ice. Coronal brain sections (30μm) were 
cut on a freezing sledge microtome (Bright 8000–001, Bright Instrument Co Ltd, UK) and stored 
in cryoprotectant (30% ethylene glycol, 20% glycerol in 0.2M phosphate buffer) at -20°C until 
further processing. 
 
For electron microscopy (EM), mice were perfused with 0.9% saline for 1min at 10ml/min 
followed by fixative (4% PFA and 2.5% glutaraldehyde in 0.2M HEPES) for 3min. After that 
brains were removed and post-fixed overnight. Slices were cut at 1mm thin then selected areas of 
striatum and cortex at 0.14mm from the bregma were dissected out and processed for EM as 
previously described10. Briefly, after primary fixation tissues were fixed for 1 h with 1.5% 
potassium ferrocyanide and 2% osmium tetroxide (weight/vol) in 0.1M cacodylate buffer and 
1% uranyl acetate at 4°C overnight. The next day, samples were dehydrated with serial dilutions 
of alcohol and embedded in TAAB Low viscosity epoxy resin (TAAB, UK). Ultrathin sections 
(70nm) were cut from resin-embedded samples on an ultramicrotome (Reichert Ultracut), 
mounted on Formvar-coated grids and viewed on a FEI Tecnai 12 Biotwin Transmission 
Electron Microscope. Images were acquired with Gatan Orius SC1000 CCD camera. 
 
Assessment of ischaemic damage 
Brain sections were stained with cresyl violet and the infarct volume was calculated by 
measuring the areas of neuronal loss at eight defined coronal levels as previously described 73, 74. 
On each section the area of damage was measured using ImageJ (NIH, Bethesda, MD, USA), 
adjusted for oedema and the volume of damage calculated by integration of areas of damage with 
the distance between coronal levels using GraphPad Prism 7, Software. The volume of damage 
was expressed as the total amount of ischaemic damage. For the assessment of haemorrhagic 
transformation, haematoxylin and eosin (H&E) staining was performed. The area of red blood 
cells was measured in the same way as the infract volume was calculated and compared between 
the groups. 
 
Assessment of BBB permeability to IgG 
To assess BBB permeability, endogenous IgG accumulation into the brain was visualised by 
peroxidase-based immunohistochemistry. Free-floating serial brain sections (30µm thick) were 
washed 3 times with PBS and endogenous peroxidase activity and non-specific staining were 
blocked by 10min incubation in 0.3% H2O2 followed by washing (3 times in PBS, 10min each). 
After that 1h blocking with 10% normal horse serum (NHS) in 0.3% Triton X-100 PBS (PBST) 
was performed before overnight incubation with biotinylated anti mouse IgG (1:250 in in 0.3% 
PBST, Vector Laboratories) at 4°C. Sections were then incubated with avidin–biotin–peroxidase 
complex, and colour-developed using a freshly prepared diaminobenzidine (DAB) solution. To 
ensure comparable DAB staining between sections is achieved, the time of the colour change 
was recorded, and DAB applied for each subsequent sample for same amount of time. 
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Immunohistochemistry 
Free-floating serial brain sections (30µm thick) were washed 3 times in PBS for 10min and 
blocked for 1h in 10% normal goat serum (NGS) in 0.3% PBST. This was followed by an 
overnight incubation with primary antibody in 2% NGS in PBST at 4°C. The primary antibodies 
used in the study are explained in details below; Chicken antiGFAP (abcam AB4674, 1:500), 
Rabbit antiIb1a (Wako 019-19741, 1:500 DF), Rat Anti-mouse CD31 (BD Pharmingen, 550274, 
1:100), Mouse anti-mouse Cav1 (BD Biosciences, 1, 610407, 1:50 ), Mouse anti-mouse NeuN 
(Millipore, MAB377, 1:100), and Rabbit Anti-MBP (Abcam, ab40390, 1:200). After incubation 
with the primary antibodies sections were washed 3 times in PBS and incubated with 
fluorescently labelled secondary antibodies in 2% NGS in PBST. To visualise the primary 
antibodies, the following secondary antibodies were used; goat anti-Ck Alexa Fluor® 488 
conjugate (Invitrogen A11039, 1:500), goat anti-Rabbit Alexa Fluor® 647 conjugate (Invitrogen, 
A21244 1:200), goat anti-mouse Alexa Fluor® 488 conjugate (Invitrogen A11001, 1:500), goat 
anti-Rat Alexa Fluor® 647 conjugate (Invitrogen, A-21247, 1:200). At the end samples were 
washed 3 times in PBS and transferred on non-gelatine coated slides and left to dry overnight 
before slides were then coverslip with ProLong Gold Antifade Mountant with DAPI (Thermo 
Fischer Scientific, Inc., USA). Images were collected on either SP5 inverted microscope (for 
Cav1-1/CD31 & NeuN/MBP) or SP8 inverted microscope (for Iba1/GFAP) using 63x objective 
in the striatum and the outer cortex at bregma -0.58 mm. Total microglia were counted and the 
percentage of DiI-Lp positive microglia recorded. The activation state of microglia was scored 
on activation scale of 0-3 based on their morphologies using a scoring system described before 
75.  
 
Data and statistical analyses 
Statistical analysis of the data was performed using Graph Pad Prism 7 software. Two-tailed 
unpaired student t-test and one-way analysis of variance followed by the Tukey multiple 
comparison test were used and p values < 0.05 were considered significant. For all analyses, data 
are represented as mean ± standard error of the mean (SEM), unless otherwise indicated. 
 
Associated Content  
Supporting Information  
Supporting Information is available free of charge on the ACS Publications website  
These include: Figure S1: Physicochemical characterisations of DiI-Lp, Figure S2: 
Characterisation of 111In-Lp, Figure S3: IVIS Lumina II imaging of the brain with and without 
transcardiac perfusion, Figure S4: Selective liposomal accumulation into ischaemic cerebral 
cortex, Figure S5: Selective liposomal accumulation into the ipsilateral striatum 24h after I.V 
administration, Figure S6: Confocal images of Cav-1 expression and DiI-Lp accumulation in 
contralateral striatum and contralateral cortex (2h after DiI-Lp I.V administration), Figure S7: 
Confocal images of Cav-1 expression and DiI-Lp accumulation in contralateral striatum and 
contralateral cortex (24h after DiI-Lp I.V administration), Figure S8: Evaluation of DiI-Lp co-
localisation with microglia and astrocytes in the ipsilateral cortex, Figure S9: Confocal images of 
DiI-Lp co-localisation with neurons and oligodendrocytes in the ipsilateral striatum, Figure S10: 
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Confocal images of DiI-Lp co-localisation with neurons and oligodendrocytes in the ipsilateral 
cortex. 
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Figure 1: Selective liposomal accumulation into the ischaemic brain shortly after Lp-DiI I.V 
administration. Selective recruitments of DiI-Lp into the ischaemic region of the brain in MCAo 
model of stroke were studies by (A) IVIS Lumina II imaging system showing the selective 
accumulation of liposomes into the ischaemic left side of brain as early as 2h after DiI-Lp I.V 
administration. Minimum DiI-Lp signal was detected from the contralateral side of the brain (right) 
and healthy mice (naive mice injected with liposomes). (B) Quantification of the fluorescent single 
of DiI-Lp in the brain by IVIS Lumina imaging software was performed by drawing a region of 
interest (ROI) that covers the whole brain and expressed as total efficiency. Colour scale of epi-
fluorescent signal range from min= 2.00-4 (red) to max= 1.00-3 (blue). A bi-phasic recruitment of 
DiI-Lp into the ischaemic area was observed showing significant increase when injected 0.5h or 
48h following MCAo and reperfusion. (C) Quantification of the volume of ischaemic damage was 
performed on representative sections taken at eight defined coronal levels. (D) Brain sections from 
healthy mice and mice after MCAo showing; maximum selective recruitment of DiI-Lp into 
ischaemic left side of the brain (marked by dashed white lines at 0.5-2.5h and 48-50h time point), 
compared to less liposomal accumulation at 4-6h and 24-26h groups and no liposomes 
accumulation into the healthy brain. Accumulation of liposomes into the ischaemic brain have a 
similar distribution to the endogenous IgG leakage into the brain (outline by dashed black lines) 
that is used as indication of BBB disruption. Cresyl violet staining of brain sections represents the 
extent of brain damage induced at different time points following 20min MCAo. In most cases 
moderate to extensive damage of both cortical and subcortical regions was observed at 1-2d post 
MCAo. Cerebral accumulation of DiI-Lp given at the early phase after reperfusion (0.5h & 4h) 
were observed before clear histological evidence of neuronal damage was observed as indicated 
from the cresyl violet stain. H&E images confirmed that liposomal accumulation was associated 
with rare instances of vessel lumen collapse (white arrows). Inset images represent 40 x 
magnifications for DiI-Lp and 20x magnification for IgG, cresyl violet and H&E. Statistical 
analysis of B&C was performed using one-way analysis of variance followed by the Tukey 
multiple comparison test and p values < 0.05 were considered significant. n=6-9 in each group. 
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Figure 2: Selective liposomal accumulation into ischaemic brain 24h after I.V 
administration. (A) Schematic presentation of the experimental time points used for DiI-Lp I.V 
administration following 20min MCAo and reperfusion. The time points of DiL-Lp intravenous 
injection illustrated the separate groups studied each received single injection. Selective 
recruitments of DiI-Lp into the ischaemic region of the brain in MCAo model of stroke were 
studies by (B) IVIS Lumina II imaging system showed that selective accumulation of liposomes 
into the ischaemic (left side) persists 24h after DiI-Lp I.V administration. (C) Quantification of the 
total fluorescent single of DiI-Lp in the brain 24h after injection indicated that there was no change 
in liposomal accumulation when injected 0.5h after MCAo, whereas reduced total liposomal level 
was observed when injected 48h after MCAo. Colour scale of epi-fluorescent signal range from 
min= 2.00-4 (red) to max= 1.00-3 (blue). A bi-phasic recruitment of DiI-Lp into the ischaemic area 
was observed showing significant increase when injected 0.5h or 48h following MCAo and 
reperfusion. (D) Cerebral accumulations of DiI-liposomes administered 0.5h & 48h after 
reperfusion were still observed in the ischaemic region 24h afterwards and observed co-localised 
with BBB damage (endogenous IgG) and infarct area (Cresyl violet) with rare evidence of vessel 
lumen collapse (H&E) indicated by white arrows. Inset images represent 40 x magnifications for 
DiI-Lp and 20x magnification for IgG, cresyl violet and H&E. Primary brain injury after MCAo 
was confirmed by (E) Quantification of volume of ischaemic damage on representative sections 
taken at eight defined coronal levels of brain tissues stained with cresyl violet, (F) measuring focal 
deficit scoring (0-28) and (G) foot-fault test. Statistical analysis of C was performed using one-
way analysis of variance followed by the Tukey multiple comparison test, n=4-6 in each group. 
Two-tailed unpaired student t-test used for statistical analysis of the data in E,F & G (n=3-4 in each 
group). p values < 0.05 were considered significant. 
29 
 
 
****
**
E F
C
A
NS
Ipsilateral Contralateral G CSF
NS
Start of 
Occlusion
End of 
Occlusion
-20’ 0 0.5
Time of reperfusion (h)
Time of DiI-Lp I.V administration after reperfusion
48
SPECT/CT imaging (0-1h & 24h after DiI-Lp I.V injection)
MCAo model
(20 mins) followed by 
reperfusion
Radiolabelling efficiency
B
Cut & count (24h after DiI-Lp I.V injection)
0-1h after I.V 24h after I.V
H
e
a
lt
h
y
M
C
A
o
+
0
.5
h
M
C
A
o
+
4
8
h
D
NS
T
im
e
 o
f 
11
1
In
-L
p
I.
V
24.5 72
0.5-24.5 48-72
Time after MCAo (h)
0.5-24.5 48-72
Time after MCAo (h)
0.5-24.5 48-72
Time after MCAo (h)
Healthy0.5-24.5 48-72
Time after MCAo (h)
Healthy0.5-24.5 48-72
Time after MCAo (h)
Healthy
111In free111In-Lp111In free111In-Lp
30 
 
Figure 3: Quantification of liposomes accumulation into the brain after MCAo. (A) Schematic 
presentation of experimental design and 111In-Lp radiolabelling efficiency. To quantify and study 
the accumulation of liposomes into the brain in real-time SPECT/CT imaging and gamma counting 
of the liposomes were performed after radiolabelling with 111In. The immobile spot on the TLC 
strips indicated the percentage of radiolabelled 111In-Lp, while free 111In was detected as the mobile 
spots near the solvent front. Very minimum free 111In was detected in the 111In-Lp samples. The 
radiolabelling stabilities of the final product of 111In-Lp were studied at 37°C after incubation in 
PBS and 50% serum for up to 48h. TLC Data indicated > 85% radiolabelling efficiency with 
excellent serum stability. The time points represent separate groups each received single injection 
of 111In-Lp intravenously. (B) Representative SPECT/CT imaging confirmed the selective 
accumulation of the liposomes into the ipsilateral side of the brain (left) compared to contralateral 
side. In the absence of ischaemic stroke, no accumulation of 111In-Lp was detected. Assessment of 
(C) neurological focal deficit scoring (0-28) and (D) foot-fault test showed no significant 
differences between 0.5h (MCAo +1d) and 48h groups (MCAo +3d). Quantification of 111In-Lp 
accumulation into (E) ipsilateral brain side and (F) contralateral brain side. Values are expressed 
as % of I.D ± SEM per gram brain tissue. Data confirmed significant increase in selective brain 
liposomal level when injected at 0.5h after MCAo and to a less extent when given 48h after MCAo. 
(G) Detection of 111In-Lp in the CSF after MCAo indicated no significant differences in CSF 
liposomal level compared to healthy control group. The data in C & D were analysed by two-tailed 
unpaired student t-test (n=3-4), where as one-way analysis of variance followed by the Tukey 
multiple comparison test (n=4-5) was used for graph E,F & G. The data were considered significant 
if p values < 0.05. 
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Figure 4: Mechanism of selective liposomal accumulation into ischaemic brain. (A) Schematic 
presentation of the experimental plan and the time frame for DiI-Lp intravenous administration 
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after 20min of MCAo model in mice. The time points represent separate groups each received 
single injection of DiI-Lp intravenously. The two possible mechanisms of selective liposome 
recruitment into the ischaemic brain are elucidated. (B) Representative TEM images confirmed 
ultrastructural changes in endothelial cells after MCAo compared to healthy mice. Amplification 
of transcytotic vesicles (indicated by red arrow head) number was clearly evident at 0.5-2.5h and 
48-50h after MCAo. Enlargement of the vesicles and ultrastructural changes to endothelial cells 
TJs (protrusions and change in morphology) were observed at late but not early time points after 
MCAo. (C) Representative images demonstrating immunofluorescence labelling of endothelial 
CD31 (cyan) and Cav-1 (green) markers in the striatum at -0.58mm from the bregma. White 
triangles represent areas of low Cav1 expression in healthy brain. Analysis was performed 2h after 
I.V injection of DiI-Lp for each group. A biphasic increase in Cav-1 immunofluorescence was 
observed for 0.5-2.5h and 48-50h groups that co-localises with the areas of DiI-Lp leakage into 
the ischaemic brain. On the contrary, Cav-1 expression and accumulation of DiI-Lp in the brain 
were minimum for 4-6h and 24-26h groups. (D) Quantitative analysis of Cav1 co-localisation with 
DiI-Lp 2h after I.V injection confirmed the biphasic pattern observed from confocal images. (E) 
Uptake of DiI-Lp by hCMEC/D3 brain endothelial cells in vitro expressed as % of control cells 
treated with vehicle showed a significant inhibition of DiI-Lp uptake in the presence of dynasore. 
(F) Evaluation of DiI-Lp leakage into the ischaemic brain 24h following I.V into MCAo mice at 
0.5h and 48h following reperfusion. Co-localisation of DiI-Lp with areas of enhanced Cav-1 
expression were detected. Cardiac perfusion was performed to remove any DiI-Lp from the 
circulation. Statistical analysis of the results in D was performed using one-way analysis of 
variance followed by the Tukey multiple comparison test, n=3-4 in each group. p values < 0.05 
were considered significant. 
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Figure 5: Co-localisation of liposomal accumulation into ischemic brain with transcellular 
and paracellular markers. (A) schematic presentation of study design for multiphoton imaging. 
In this study each mouse received I.V injections of DiI Lp (25mM, 100µL), cascade blue dextran 
3K (50µL) and albumin-Alexa488 (50µL) either in the early phase (MCAo+0.5h) or delayed phase 
(MCAo+48h) after stroke. (B&C) Mice imaged with SP8 upright multiphoton microscope using 
25x lense with water immersion. This region of interest exposes the somatosensory area of the 
cortex (specifically the barrel cortex) that is most affected by the MCAo. Imaging performed 30 
min and 2h after injections represented the distribution of dextran (cyan), albumin (green) and DiI-
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Lp (red) into the ipsilateral brain. The wide view images in (B) and (C) are 442 µm wide and the 
130 µm wide ROI outlined by the white square is shown below each image. (D) At the end of the 
experiment mice were perfused with saline and fixed with PFA and the brains were collected and 
imaged with IVIS Lumina II imaging system. (E) Quantification of the fluorescent single of 
dextran, albumin and DiI-Lp in the brain by IVIS Lumina imaging software was performed by 
drawing ROI that covers the whole brain and the data expressed as total efficiency. Colour scale 
of epi-fluorescent signal range from min= 1.00-5 to max=3.00-4 for dextran and albumin and from 
min= 1.00-5 to max=6.00-4 for DiI-Lp. Statistical analysis of the graphs presented in E was 
performed using one-way analysis of variance followed by the Tukey multiple comparison test, 
n=3 in each group. p values < 0.05 were considered significant. 
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Figure 6: Evaluation of DiI-Lp co-localisation with microglia and astrocytes. Representative 
confocal images showing co-localisation of DiI-Lp with of Iba1 (activated microglial marker) and 
GFAP (astrocytes marker). Brain sections were analysed 24h following the injection of DiI-Lp 
intravenously into MCAo mice in the; (A) early phase (MCAo+0.5h) and (B&C) delayed phase 
(MCAo+48h) after reperfusion. (D) Scoring system of microglial activation showing 
representative images of the different stages of microglial cells activation on a scale from 0-3. (E) 
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Schematic summary of liposomal co-localisation with microglia and astrocytes. (F) Quantification 
of DiI-Lp co-localisations indicated significant uptake of DiI-Lp by microglia when injected 48h 
after MCAo. (G) The correlations of DiI-Lp uptake by microglia with the different stages of 
microglial activation after MCAo. Significant uptake of liposomes by activated microglial was 
observed compared to minimum uptake by resting microglia (H) No significant uptake of DiI-Lp 
into astrocytes was detected. Statistical analysis of G was performed using one-way analysis of 
variance followed by the Tukey multiple comparison test, n=3 in each group. Two-tailed unpaired 
student t-test used for statistical analysis of the data in F&H (n=3-4) in each group). p values < 
0.05 were considered significant. 
 
